Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.35 |
| ▸ | DPEP1 | P16444 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5659416 | 0.89 | POLB (0.37) | MEN1KMT2AHSD11B1DPP4POLB | |
| SCHEMBL5655978 | 0.87 | RECQL (0.38) | TSHRKMT2AGAADPP4POLB | |
| SCHEMBL5660846 | 0.87 | DPP4 (0.42) | DPP4POLB | |
| SCHEMBL5658025 | 0.86 | MEN1 (0.34) | MEN1HPGDTSHRKMT2AGAA | |
| SCHEMBL5656723 | 0.84 | GRM3 (0.42) | HPGDGAAPOLB | |
| SCHEMBL5657247 | 0.82 | ALDH1A1 (0.35) | MEN1KMT2ADPP4POLB | |
| SCHEMBL5659925 | 0.80 | ALDH1A1 (0.48) | MEN1HPGDKMT2AGAATDP1 | |
| SCHEMBL5659712 | 0.80 | MEN1 (0.38) | MEN1HPGDTSHRKMT2A | |
| SCHEMBL5658023 | 0.78 | MEN1 (0.40) | MEN1HPGDTSHRKMT2A | |
| SCHEMBL5657935 | 0.77 | DPP4 (0.33) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7192953-B2 | Antibacterial agents | VERNALIS (OXFORD) LIMITED (GB) | 2007-03-20 | — | — | US | disclosed |
| US-20060128811-A1 | Hydroxamic acid- and N-formyl hydroxylamine hydrazide derivatives; veterinary medicine | VERNALIS (OXFORD) LIMITED (GB) | 2006-06-15 | — | — | US | disclosed |
| EP-1567504-A1 | ANTIBACTERIAL AGENTS | Vernalis (Oxford) Ltd (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050638-A1 | ANTIBACTERIAL AGENTS | VERNALIS (OXFORD) LTD. (GB) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128811-A1 | Hydroxamic acid- and N-formyl hydroxylamine hydrazide derivatives; veterinary medicine | HRH2, HCAR3, HCAR2 | MEN1 2084/4885HPGD 359/4885TSHR 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.